Search
Profound Medical Corp
PROFAdd to Watchlist
6.810USD
+0.060+0.89%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
247.46MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.89%
5 Days
+4.77%
1 Month
+0.29%
6 Months
-11.10%
Year to Date
-13.47%
1 Year
+13.97%
Key Figures
6.830Open
6.900High
23.19KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.06%Turnover Ratio
6.750Prev. Close
6.750Low
104.61KTurnover
LossP/E Static
4.16P/B
0.00%Div Yield TTM
-57.92%ROA
12.40052wk High
1.10Volume Ratio
-27.82MNet Profit
36.34MShares
-1.2454EPS TTM
0.52Beta
-70.59%ROE
5.23052wk Low
2.22%Amplitude
71.80%Gross Margin
247.46MMarket Cap
-0.14Reward/Risk
4.13%Risk Rate
TradingKey Stock Score of Profound Medical Corp
Currency: USD Updated: 2026-07-02Key Insights
Profound Medical Corp's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 108 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.05.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Profound Medical Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Profound Medical Corp Highlights
StrengthsRisks
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 123.61% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 16.10M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 16.10M.
Fairly Valued
The company’s latest PE is -5.47, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 17.27M shares, increasing 8.83% quarter-over-quarter.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
11.050
Target Price
+63.70%
Upside Space
Profound Medical Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Profound Medical Corp Info
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Ticker SymbolPROF
CompanyProfound Medical Corp
CEOMenawat (Arun Swarup)
Websitehttps://profoundmedical.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Profound Medical Corp (PROF)?
The current price of Profound Medical Corp (PROF) is 6.81.
What is the symbol of Profound Medical Corp?
The ticker symbol of Profound Medical Corp is PROF.
What is the 52-week high of Profound Medical Corp?
The 52-week high of Profound Medical Corp is 12.40.
What is the 52-week low of Profound Medical Corp?
The 52-week low of Profound Medical Corp is 5.23.
What is the market capitalization of Profound Medical Corp?
The market capitalization of Profound Medical Corp is 247.46M.
Is Profound Medical Corp (PROF) currently rated as Buy, Hold, or Sell?
According to analysts, Profound Medical Corp (PROF) has an overall rating of Buy, with a price target of 11.05.
What is the Earnings Per Share (EPS TTM) of Profound Medical Corp (PROF)?
The Earnings Per Share (EPS TTM) of Profound Medical Corp (PROF) is -1.41.